UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.